Beyond the well-established biomarkers—such as pH, lactate, glucose, creatinine, troponin, procalcitonin, and proBNP—new biomarkers have been identified as potentially valuable for CS risk stratification. The gene discussed is NPPB; the disease is Cowden syndrome 1.